Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01.

In previously treated locally recurrent or metastatic triple-negative breast cancer, sacituzumab tirumotecan improved overall survival versus chemotherapy, with median OS 14.7 vs 9.9 months (HR 0.60).

• Why it matters: The trial addressed whether the earlier overall survival advantage seen at interim analysis would persist with longer follow-up in advanced TNBC.
• What they did: In OptiTROP-Breast01, 263 patients were randomized 1:1 to sac-TMT (n=130) or chemotherapy (n=133), and final OS was analyzed at a median follow-up of 29.4 months.
• The result: The OS benefit was sustained at final analysis (30-month OS 26.8% vs 13.2%), and after adjustment for subsequent ADC therapy, median OS was 14.7 vs an estimated 9.4 months (HR 0.55).

AI summary of the abstract · may contain errors · not medical advice · read the paper.